Ocugen's stock bounces after 'positive' results from COVID-19 vaccine candidate in children as young as 2 years oldMarket Watch • 12/30/21
Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data From COVAXIN™ (BBV152), COVID-19 Candidate Vaccine, in Children 2 – 18 YEARSGlobeNewsWire • 12/30/21
Ocugen, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 12/20/21
Ocugen Partnered COVID-19 Vaccine Candidate Generates Immune Memory At Least 6 Months After VaccinationBenzinga • 12/15/21